Pediatric embryonal brain tumors in the molecular era

Expert Rev Mol Diagn. 2020 Mar;20(3):293-303. doi: 10.1080/14737159.2020.1714439. Epub 2020 Jan 15.

Abstract

Introduction: Embryonal brain tumors (EBTs) are highly aggressive malignancies predominantly affecting children. They include medulloblastoma (MB), atypical rhabdoid/teratoid tumors (ATRT), pineoblastoma (PB), embryonal tumor multiple rosettes (ETMR)/C19MC-altered tumors, and newly recognized embryonal tumors with FOXR2 activation or BCOR alteration.Areas covered: This review will provide a comprehensive overview and updated of the literature on each of these EBTs. The evolution from location- and histopathology-based diagnosis to more specific and robust molecular-based classification schemes, as well as treatment modalities, will be discussed.Expert commentary: The subgrouping of EBTs with multi-omic profiling has had important implications for risk stratification and discovery of targetable driver pathways. However, these innovations are unlikely to significantly improve survival among high-risk patients until robust preclinical studies are conducted, followed by validation in biology-informed clinical trials.

Keywords: Atypical teratoid rhabdoid tumor ATRT; C19MC-altered tumor; embryonal tumor multiple rosettes ETMR; medulloblastoma; pineoblastoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Age Factors
  • Biomarkers, Tumor
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / etiology*
  • Brain Neoplasms / therapy
  • Child
  • Diagnosis, Differential
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Neoplasms, Germ Cell and Embryonal / diagnosis*
  • Neoplasms, Germ Cell and Embryonal / etiology*
  • Neoplasms, Germ Cell and Embryonal / therapy

Substances

  • Biomarkers, Tumor